CMV IgM at 13 Weeks: Does This Mean Primary Infection?
A 31-year-old nursery nurse, 13 weeks into her first pregnancy, is referred after booking serology. The peripheral laboratory reports (ELISA, no avidity testing on site): CMV IgM index 2.9 (cut-off 1.0), CMV IgG 58 AU/mL (positive, cut-off 6), rubella IgG positive, toxoplasma IgG and IgM negative. She had a flu-like illness with fever and fatigue about seven weeks ago. Her obstetric record contains no CMV serology from before this pregnancy, and no stored sample exists. Her 12-week ultrasound is normal. She is extremely anxious and asks whether she should terminate the pregnancy. The obstetrician asks whether IgM positivity is sufficient to diagnose primary infection, and whether amniocentesis should be arranged now.
1. Can primary CMV infection be diagnosed from these results alone? Explain the limitations of IgM testing and what the laboratory should do next.
Read the worked answer
No. A positive CMV IgM cannot establish primary infection, and acting on it alone is the commonest error in this scenario.
Why IgM is unreliable
- IgM can persist for 6–9 months and sometimes longer after primary infection, so a positive result may reflect infection acquired before conception.
- It can be produced during reactivation or reinfection.
- False positives occur through cross-reacting antibodies (EBV, parvovirus, rheumatoid factor), non-specific polyclonal stimulation, and assay interference; the positive predictive value of IgM in a low-prevalence pregnant population is poor.
- The IgG titre of 58 AU/mL is consistent with established immunity as well as with recent infection - a single value gives no kinetic information.
The decisive test is IgG avidity, performed on the same serum at a reference laboratory:
- High avidity indicates maturation of the antibody response, which takes at least 3 months; high avidity in the first trimester effectively excludes primary infection in the previous 3 months, so infection predates conception (or occurred very early) and fetal risk is minimal.
- Low avidity indicates primary infection within roughly the last 3 months and makes recent infection likely, especially with a compatible clinical illness.
- Borderline avidity requires a repeat in 2–4 weeks - rising IgG and falling avidity index confirm recent infection.
Also ask the reference laboratory to perform an immunoblot/line assay (IgM/IgG to specific CMV antigens) to resolve the non-specific IgM, and repeat the sample in 2–3 weeks to look for a rise in IgG.
2. If avidity is low, when and how should fetal infection be investigated, and what are the limits of those tests?
Read the worked answer
Timing of invasive testing
Amniocentesis is not useful at 13 weeks. The standard is:
- at or after 21 weeks' gestation, and
- at least 6 weeks after the estimated date of maternal infection (the seven-week illness is helpful here).
This delay is physiological: the virus must be shed in fetal urine and reach the amniotic fluid in sufficient quantity, and renal function must be adequate. Testing earlier gives false negatives.
Test
- CMV DNA PCR on amniotic fluid is the test of choice; amniotic fluid viral load (particularly >10³ copies/mL) correlates with symptomatic infection.
- Cordocentesis and fetal blood sampling are not recommended for diagnosis because of procedure-related risk.
Performance and limits
- Sensitivity is around 90% and specificity around 97% when performed at the correct gestation and interval; a negative result markedly reduces, but does not eliminate, the chance of fetal infection.
- A positive result confirms fetal infection but does not predict severity; most infected fetuses are asymptomatic at birth.
Adjuncts
- Serial ultrasound (microcephaly, ventriculomegaly, echogenic bowel, cerebral calcification, growth restriction, hepatosplenomegaly) and fetal MRI at 28–32 weeks for cerebral findings.
- Newborn: urine or saliva PCR within the first 3 weeks of life, and brainstem auditory evoked responses.
Counselling should be non-directive: after primary infection in the first trimester, transmission is around 30–40%, roughly 10–15% of infected infants are symptomatic at birth, and sensorineural hearing loss may develop later in a further proportion. The decision about continuing the pregnancy belongs to the couple, informed by the amniocentesis result and serial imaging rather than by the IgM value.